Registry of Endovascular Treatment for Vertebrobasilar Dissecting Aneurysms in China
Launched by BEIJING TIANTAN HOSPITAL · Aug 2, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called vertebrobasilar dissecting aneurysms (VBDAs), which are a type of blood vessel problem in the brain that can lead to strokes, especially in younger people. The researchers want to better understand how different treatments, such as careful observation or specific medical procedures, can help patients with this condition. They are looking for individuals aged 18 to 80 who have been diagnosed with an unruptured (not burst) aneurysm and have had the necessary brain scans.
Participants in this study will be closely monitored, and their treatment options will be tailored to their individual needs. They may be placed in one of three groups: those who will be observed, those who will receive a stent to help support the blood vessel, or those who will get a different type of treatment called a flow diverter. This trial aims to improve how we diagnose and treat this challenging condition, and it hopes to provide clearer guidelines for doctors in the future. If you or a loved one is eligible and interested, you can consider joining this important research effort.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18-80 years old;
- • 2. Patients diagnosis of "unruptured vertebrobasilar dissecting aneurysm".
- Exclusion Criteria:
- • 1. Patients did not undergo a cranial MRI;
- • 2. Missing critical clinical baseline;
- • 3. Missing pre-treatment imaging;
- • 4. Receiving microsurgery;
- • 5. The combination of other serious diseases during diagnosis will significantly affect the follow-up of patients;
- • 6. CT/MRI shows intracranial hemorrhage or subarachnoid hemorrhage (SWI microbleeds are ignored).
About Beijing Tiantan Hospital
Beijing Tiantan Hospital, affiliated with Capital Medical University, is a leading medical institution in China renowned for its expertise in neurology, neurosurgery, and various other specialties. As a prominent clinical trial sponsor, the hospital is committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on high-quality clinical trials, Beijing Tiantan Hospital adheres to rigorous ethical standards and regulatory requirements, fostering collaboration with academic institutions and industry partners to facilitate the development of cutting-edge therapies and interventions. Its state-of-the-art facilities and experienced research team enable the hospital to play a pivotal role in the global medical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported